Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.

Abstract

The aim of this study was to assess the prognostic role of soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease (HD) both in the achievement of complete remission (CR) and in predicting disease relapse. Between August 1988 and June 1993 sIL-2R serum levels were measured in 174 untreated patients; in 137 of them evaluation was repeated at the end of treatment and in 132 also during the follow-up. Baseline sIL-2R levels (mean+/-standard error) were significantly higher in patients than in 65 healthy control subjects (1842+/-129 U ml(-1) vs 420+/-10 U ml(-10, P< 0.0001). At the end of treatment 135 out of 137 evaluated patients achieved complete response (CR) and their mean sIL-2R serum levels were significantly lower than those at diagnosis (635+/-19 U ml(-1) vs 1795+/-122 U ml(-1), P=0.0001). After a median follow-up of 5 years, sIL-2R remained low in 114 patients in continuous CR, while they increased in 9 out of 12 patients (75%) who relapsed. However, a temporary increase was also observed in six patients (5%) still in CR. Treatment outcome in terms of freedom from progression was linearly related to sIL-2R levels. Our study confirms that patients with untreated HD have increased baseline levels of sIL-2R compared with healthy subjects and that their pretreatment values may be an indication of disease outcome similar to other conventional prognostic factors, such as number of involved sites, presence of B symptoms and extranodal extent.

• Authors: S Viviani, E Camerini, V Bonfante, A Santoro, M Balzarotti, M Fornier, L Devizzi, P Verderio, P Valagussa, G Bonadonna
• Journal: British journal of cancer (Br J Cancer) Vol. 77 Issue 6 Pg. 992-7 (Mar 1998) ISSN: 0007-0920 [Print] England
• PMID: 9528846 (Publication Type: Journal Article)

Chemical References

• Biomarkers, Tumor
• Receptors, Interleukin-2
• Bleomycin
• Procarbazine
• Epirubicin
• Mechlorethamine
• Vincristine
• Vinblastine
• Etoposide
• Dacarbazine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Adolescent
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Biomarkers, Tumor (blood)
• Bleomycin (administration & dosage)
• Combined Modality Therapy
• Confidence Intervals
• Cyclophosphamide (administration & dosage)
• Dacarbazine (administration & dosage)
• Disease-Free Survival
• Doxorubicin (administration & dosage)
• Epirubicin (administration & dosage)
• Etoposide (administration & dosage)
• Female
• Hodgkin Disease (blood, pathology, therapy)
• Humans
• Lymph Nodes (pathology)
• Male
• Mechlorethamine (administration & dosage)
• Middle Aged
• Neoplasm Staging
• Prednisone (administration & dosage)
• Procarbazine (administration & dosage)
• Receptors, Interleukin-2 (blood)
• Recurrence
• Reference Values
• Retrospective Studies
• Vinblastine (administration & dosage)
• Vincristine (administration & dosage)